Stock Events

Stock Events

MaxCyte 

€1.0900
25
+€0.03+2.83% Friday 19:56

Statistics

Day High
1.1
Day Low
1.06
52W High
1.37
52W Low
0.54
Volume
-
Avg. Volume
-
Mkt Cap
112.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q1 2026
Q2 2026
Next
-0.08
-0.06
-0.05
-0.03
Expected EPS
-0.07101600000000001
Actual EPS
N/A

Financials

-134.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
28.86MRevenue
-38.72MNet Income

Analyst Ratings

3.79Average Price Target
The highest estimate is 3.79.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYE0.STU. It's not an investment recommendation.
Tesla
7
TSLA
Apple
6
AAPL
Amazon
6
AMZN
NVIDIA
5
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific offers a range of cell engineering and life sciences solutions, competing in the cell therapy tools space with MaxCyte.
Danaher
DHR
Mkt Cap151.89B
Danaher, through its subsidiaries, provides bioprocessing technologies, including cell therapy manufacturing, competing with MaxCyte's cell engineering platforms.
Bio-Rad Laboratories
BIO
Mkt Cap10.37B
Bio-Rad Laboratories provides products and services for life science research and clinical diagnostics, including cell biology, competing with MaxCyte's offerings.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers genomic analysis solutions, and its advancements in gene editing and sequencing technologies present competition to MaxCyte's cell engineering technologies.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides sequencing and array-based solutions for genetic analysis, indirectly competing with MaxCyte by advancing gene editing and cell therapy research.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading genome editing company that competes with MaxCyte in the development of therapies using CRISPR/Cas9 technology.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing field, directly competing with MaxCyte in the development of CRISPR-based therapeutics.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on the development of gene-based medicines, including CRISPR/Cas9 technology, competing with MaxCyte in gene editing applications.

About

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Show more...
CEO
Maher Masoud
Employees
91
Country
United States
ISIN
US57777K1060
WKN
000A2AGVE

Listings

STU
DE
MYE0.STU
F
DE
MYE0.F
MU
DE
MYE0.MU
BOATS
BOATS
MXCT.BOATS

0 Comments

Share your thoughts

FAQ

What is MaxCyte stock price today?▼
The current price of MYE0.STU is €1.09 EUR — it has increased by +2.83% in the past 24 hours. Watch MaxCyte stock price performance more closely on the chart.
What is MaxCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange MaxCyte stocks are traded under the ticker MYE0.STU.
Is MaxCyte stock price growing?▼
MYE0.STU stock has risen by +4.81% compared to the previous week, the month change is a +18.48% rise, over the last year MaxCyte has showed a +3.81% increase.
What is MaxCyte market cap?▼
Today MaxCyte has the market capitalization of 112.49M
When is the next MaxCyte earnings date?▼
MaxCyte is going to release the next earnings report on November 11, 2026.
What were MaxCyte earnings last quarter?▼
MYE0.STU earnings for the last quarter are -0.07 EUR per share, whereas the estimation was -0.08 EUR resulting in a +11.11% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is MaxCyte revenue for the last year?▼
MaxCyte revenue for the last year amounts to 28.86M EUR.
What is MaxCyte net income for the last year?▼
MYE0.STU net income for the last year is -38.72M EUR.
How many employees does MaxCyte have?▼
As of September 05, 2026, the company has 91 employees.
In which sector is MaxCyte located?▼
MaxCyte operates in the Health & Wellness sector.
When did MaxCyte complete a stock split?▼
MaxCyte has not had any recent stock splits.
Where is MaxCyte headquartered?▼
MaxCyte is headquartered in ROCKVILLE, United States.